Related Experiment Video

Updated: May 21, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung

Vassiliki Papadimitrakopoulou1

  • 1Department of Thoracic/Head and Neck Medical Oncology, UT/MD Anderson Cancer Center, Houston, Texas 77030 , USA. vpapadim@mdanderson.org

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|June 1, 2012
PubMed

Insights

Novel lung cancer therapies targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway show promise for overcoming treatment resistance and improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a prevalent disease with limited curative treatment options for advanced stages, indicating a significant unmet medical need.
  • Personalized therapy, targeting molecular drivers, is a key advancement in cancer treatment.
  • Understanding pathways driving cancer and drug resistance, such as the PI3K/AKT/mTOR pathway, is crucial for developing novel therapies.

Purpose of the Study:

  • To investigate the frequency of activating mutations within the PI3K/AKT/mTOR pathway in lung cancer.
  • To review emerging therapeutic agents designed to target this critical pathway.
  • To explore the potential role of PI3K/AKT/mTOR pathway inhibition in the clinical development of new lung cancer treatments.

Main Methods:

  • Examination of mutation frequencies in the PI3K/AKT/mTOR pathway.
  • Review of novel therapeutic agents targeting the PI3K/AKT/mTOR pathway.
  • Analysis of the potential clinical applications of pathway inhibition strategies.

Main Results:

  • The PI3K/AKT/mTOR pathway is frequently activated in lung cancer patients.
  • Activation of this pathway is also observed in tumors resistant to other targeted therapies.
  • Novel agents targeting the PI3K/AKT/mTOR pathway are under investigation for their therapeutic potential.

Conclusions:

  • Targeting the PI3K/AKT/mTOR pathway offers a promising strategy for lung cancer treatment.
  • Inhibition of this pathway may overcome resistance to existing therapies and improve treatment efficacy.
  • Further clinical development of PI3K/AKT/mTOR inhibitors is warranted for lung cancer patients.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...